2
项与 Anti-CD20/CD30 CAR-T Cells(Shanghai First Song Biotechnology) 相关的临床试验An Exploratory Clinical Study of Autologous Anti-CD20/CD30 Chimeric Antigen Receptor T Cells (anti-CD20/CD30 CAR-T Cells) in Subjects with Relapsed/Refractory Lymphoma
This study is an exploratory clinical trial of a single-center, open-label, single-dose treatment of anti-CD20/CD30-CAR-T cells in subjects with relapsed/refractory lymphoma.
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CD19-CAR-T Cell Therapy in Subjects With Relapsed/Refractory B Cell Malignancies
This is a single-center, single-arm, open-label, exploratory study to determine the safety, tolerability, feasibility, and preliminary anti-tumor activity of anti-CD19-CAR-T cells in subjects with relapsed/refractory (r/r) B-cell malignancies.
This study plans to enroll patients with relapsed/refractory CD19-positive B-cell malignancies, who will receive a single infusion of anti-CD19-CAR-T cells after screening, PBMC collection, and lymphodepleting chemotherapy.
100 项与 Anti-CD20/CD30 CAR-T Cells(Shanghai First Song Biotechnology) 相关的临床结果
100 项与 Anti-CD20/CD30 CAR-T Cells(Shanghai First Song Biotechnology) 相关的转化医学
100 项与 Anti-CD20/CD30 CAR-T Cells(Shanghai First Song Biotechnology) 相关的专利（医药）
100 项与 Anti-CD20/CD30 CAR-T Cells(Shanghai First Song Biotechnology) 相关的药物交易
